Clinical Research Directory
Browse clinical research sites, groups, and studies.
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Sponsor: University of Chicago
Summary
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Official title: Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2023-04-26
Completion Date
2026-05-01
Last Updated
2025-10-01
Healthy Volunteers
No
Interventions
Risk Map Decision Support System (DSS).
The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
Magnetic Resonance Imaging (MRI)
A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
Magnetic Resonance Imaging (MRI) Guided Biopsy
A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
Locations (1)
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States